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Gymnadenia conopsea (L.) R. Br. (Orchidaceae) is a perennial herbaceous orchid
plant that grows widely throughout Europe and in temperate and subtropical zones
of Asia. In China, its tuber has been used in traditional Chinese medicines, Tibetan
medicines, Mongolian medicines and other ethnic medicines, and taken to treat
numerous health conditions. The present paper provides a review of the traditional uses,
phytochemistry, biological activities, and toxicology to highlight the future prospects of
the plant. More than 120 chemical compounds have been isolated, and the primary
components are glucosides, dihydrostilbenes, phenanthrenes, aromatic compounds,
and other compounds. G. conopsea and its active constituents possess broad
pharmacological properties, such as the tonifying effect, anti-oxidative activity, anti-viral
activity, immunoregulatory, antianaphylaxis, antigastric ulcer, sedative, and hypnotic
activities, etc. However, overexploitation combined with the habitat destruction has
resulted in the rapid decrease of the resources of this plant, and the sustainable use
of G. conopsea is necessary to study. Meanwhile, the toxicity of this plant had not
been comprehensively studied, and the active constituents and the mechanisms of
action of the tuber were still unclear. Further, studies on G. conopsea should lead to
the development of scientific quality control and new drugs and therapies for various
diseases; thus, its use and development require additional investigation.
Keywords: Gymnadenia conopsea, traditional medicine, glucosides, tonifying activity, anti-viral activity
Abbreviations: BSA, Bovine Serum Albumin; CAT, Catalase; DNA, Deoxyribonucleic Acid; DPPH, 1,1-diphenyl-2-
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C, High Density Lipoprotein-Cholesterol; HE, Hemoglobin Electrophoresis; HIV-1, Human Immunodeficiency Virus-1;
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MeOH, Methyl Alcohol; PACE, Polysaccharide Analysis by Carbohydrate Gel Electrophoresis; PCR, Polymerase Chain
Reaction; SOD, superoxide dismutase; TC, Total Cholesterol; TCM, Traditional Chinese Medicine; TG, Triglyceride; WHO,
World Health Organization.
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INTRODUCTION
Gymnadenia conopsea (L.) R. Br. (Orchidaceae) is a perennial
herbaceous flowering plant that is distributed from 200 to
4700m altitude throughout northern Europe, including England,
Ireland, Russia, etc., and temperate and subtropical zones in
Asian countries, including Nepal, China, Japan, and the Korean
peninsula (Commission of Flora Reipublicae Popularis Sinicae,
2004; http://frps.eflora.cn/frps). For thousands of years, due to
the prominent effects on invigorating the spleen, nourishing
the lungs and blood, regenerating body fluid, and controlling
bleeding with astringents, the tubers of G. conopsea was ascribed
as a reinforcing agent of traditional medicines in China. It has
been primarily used to treat kidney asthenia, cough, and dyspnea
induced by lung asthenia, consumption diseases, neurasthenia,
chronic diarrhea, morbid leucorrhea, chronic hepatitis, and other
diseases in some Asian countries (Chinese Materia Editorial
Committee, State Chinese Medicine Administration Bureau,
2002). Because the contour of the tuber is similar to the
palm of the human hand, the tuber was given the Chinese
name Shou Zhang Shen, meaning “ginseng likes palm hands”
(Figure 1). In 1977, the tuber of G. conopsea was listed in the
Pharmacopeia of the People’s Republic of China (Committee
for the Pharmacopoeia of P.R. China, 1977). Now, it is widely
used as a folk medicine and traditional health food by Tibetans,
Mongolians, the Han people, and other ethnic groups in China.
Because of the marked therapeutic effects and nutritional
actions, researchers have widely investigated the properties
of the tuber of G. conopsea Modern pharmacological studies
have shown that it possesses broad pharmacological properties
and can be used in the following treatments: tonifying effect,
antioxidative, anti-viral, gastric ulcer prevention, anti-aging,
immunoregulatory, antianaphylaxis, sedative, hypnotic, etc.
Most of these actions have closely matched traditional uses.
The chemical compounds from this plant have also been
extensively studied, and glucosides, toluylenes, dihydrostilbenes,
phenanthrenes, aromatic compounds, and other compounds
have been isolated and identified.
In this review, advances in the ethnobotanical, phytochemical,
biological and pharmacological activities, and toxicology of
G. conopsea are presented and critical assessment. And the data
supports its use and exploitation in new drugs.
BOTANICAL DESCRIPTION
Commission of Flora Reipublicae Popularis Sinica According to
the description by Meekers et al. (2012) and the Commission
of Flora Reipublicae Popularis Sinicae (2004), Gymnadenia
conopsea (L.) R. Br. is an apolycarpic, perennial, terrestrial, and
fragrant orchid herb that belongs to the Gymnadenia genus of
Orchidaceae family, and distributs at forests, grasslands, and
waterlogged meadows from 200 to 4700m altitude. It has about
69 synonyms of this species, but only Gymnadenia conopsea (L.)
R. Br. is an accepted and approved name in the World. The
stem is 20–60 cm, erect, slim, terete, or angled above and leafy
with 2–3 brown membranous sheaths at the base. The leaves
are green with dimensions of 5.5–15 × 1–2.5 cm, and the lower
leaves are erect to slightly spreading, more, or less narrowly
oblong-lanceolate or linear-lanceolate, obtuse to subacute, and
slightly hooded at the apex, entire, keeled, and folded and have
1–2 or more veins on each side of the midrib; the upper 2–3
leaves are smaller, lanceolate or bract-like, and taper to a fine
point. The bracts are green and usually tend toward violet at the
edges, and they are lanceolate and taper to a fine point at the
apex. The raceme is 5.5–15 cm long and ranges in color from
pale pink to lilac (rarely white or bright magenta), and it is
strongly scented with a flowering season from July to August.
Inflorescence 11–26 cm, slender; peduncle with one to a few
scattered, lanceolate bracts 1.5–6 cm; rachis 4–12 cm, densely
many flowered; floral bracts lanceolate, often longer than ovary
and flower, apex long acuminate-caudate. And flowers fragrant,
pink, rarely pinkish white; ovary 5–8mm including pedicel.
Dorsal sepal broadly elliptic to broadly ovate-elliptic; lateral
sepals reflexed, obliquely ovate, 4–5.5 × 3–4mm, 3-veined,
margin revolute, apex acute. Petals obliquely ovate-triangular, 3-
veined, apex acute; lip spreading, broadly cuneate-obovate. There
are two tubers with dimensions of 14–30× 7.5–24mm; the tubers
are palmate lobed with thick segments that are tapering and
obtuse, pressed together, and split halfway to the base into 3–6
lobes. The short and thick roots are sparse and grow horizontally
or even toward the soil surface. The fruit has dimensions of 8.6–
9.3× 2.6–2.7 mm, and they are erect with six ribs. The seeds have
dimensions of 0.3 × 0.1 mm and are produced in large numbers
(http://www.theplantlist.org1; www.efloras.org2; Figure 1).
TRADITIONAL USES
G. conopsea is widely distributed in northern Europe and certain
Asian countries. Like some TCM, G. conopsea is not used in folk
medicine, and just has been considered a fragrant orchid plant in
some European countries. So, studies on the ethnopharmacology
and clinical uses of the plant have been mainly focused on Asian
countries, such as China, Nepal, and Japan.
In China,G. conopsea is primarily distributed in Heilongjiang,
Jilin, Liaoning, Hebei, Shanxi, Shangxi, Gansu, Sichuan, and
Yunnan Provinces and Inner Mongolia and Xizang Autonomous
Regions at altitudes of 265–4700m (Commission of Flora
Reipublicae Popularis Sinicae, 2004). The tuber has been
employed as a reinforcing agent of folk medicines and widely
used as traditional Chinese medicine (Han national medicine),
Tibetan medicine, Mongolian medicine, Baiyao (the Bai national
medicine), Chaoyao (the Korean national medicine), and
Naxiyao (the Naxi national medicine) to treat various diseases
in China. The tuber has also been employed as a health care
product with other medicines or food to improve the body and
prevent illness, and could be made to tincture and galenical to
treat impotence and the bronchial asthma in China and Russia,
respectively (Mamedov and Craker, 2001; Matsuda et al., 2004;
Gutierrez, 2010). But at the same time, because of the rare
resource of this plant, the tuber of Gymnadenia crassinervis,
Coeloglossum viride var. bracteatum, and Spiranthea lancea have
1The Plant List, version 1 (Accessed January 01, 2010).
2The Flora of China.
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FIGURE 1 | Photographs of Gymnadenia conopsea (L.) R. Br. and the tuber. We also thanks for the provider of Figure 1, Zhou Yao from http://www.
plantphoto.cn.
been used as substitutes for G. conopsea in certain regions,
such as Tibet region (Xie et al., 2005; Zi, 2008; Xue et al.,
2009).
As a traditional Tibetan medicine, the G. conopsea tuber has
been widely used in the Tibetan region to treat lung disease
and weakening by invigorating the kidney and moisturizing
the lungs. The plant is known as “Wangla,” and it has been
recorded in the “Sibuyidian,” the classical book of Tibetan
medicine, since the eighth century. In Tibetan medicine, it
could be used as a single medicine or as one composition
mixed with other medicines to treat diseases. For example, after
grinding to powder, it (30 g) concoction with bee honey (40 g),
Rhizome Gastrodiae (30 g), Radix Phlomii (30 g), Herb Drosera
peltat (30 g), and Rhododendron parvifolium (30 g) could be used
to treat impotence, spermatorrhea, anemia, and insomnia for
3 g twice per day (Chinese Materia Editorial Committee, State
Chinese Medicine Administration Bureau, 2002). And according
to the database of Tibetan prescriptions, out of 4500 traditional
prescriptions in Tibet Autonomous Region, theG. conopsea tuber
was used 104 times (rate of 2.3%), and 33 prescriptions were
used to invigorate the body, strengthen the Yang, and lengthen
human life; 26 prescriptions were used to treat kidney diseases;
12 prescriptions were used to treat gout and arthromyodynia
diseases; 11 prescriptions were applied to treat lung disease;
7 prescriptions were used to treat eye diseases; and other
prescriptions were used to treat parasitic diseases and additional
diseases (Ji et al., 2009; Xue et al., 2009). Currently, the tuber
of G. conopsea is combined with other medicines in various
preparations to treat a number of diseases. Five preparations
have been listed in the Chinese Pharmacopeia and approved
by the State Food and Drug Administration of China of the
People’s Republic of China. Medicines such as “Shi Wei Shou
Shen Powder” and “Fu Fang Shou Shen Wan” have been widely
used to treat kidney asthenia, impotence and spermatorrhea,
among other disorders (http://www.sfda.gov.cn, 2014; Table 1).
Except the above effects on the clinic, the tuber of G. conopsea
also could be used to treat hepatitis B by folk doctors only
in the Tibetan region (Chinese Materia Editorial Committee,
State Chinese Medicine Administration Bureau, 2002). At the
same time, it has also been used as a common food item by
local people in the Tibetan region, where it is usually cooked
with vegetables and rice. For example, the tuber is used as an
important ingredient in the famous dish “Shiguo Ji” (chicken
cooked in a stone hotpot).
In the traditional Mongolian medicine, the tuber of G.
conopsea is named “Erihaoteng” and has been historically
recorded by many classical folk medicine books of the Inner
Mongolia Autonomous Region. In additional, it has been widely
used to treat kidney asthenia, lumbago and leg pain, light
scurvy, spermatorrhea, and impotence (Gege et al., 2013). The
tuber of G. conopsea and other traditional medicines have been
combined into different preparations to treat various diseases.
For example, the tuber and an additional 36medicines are known
as Shouzhangsheng-37 pills, which are used to treat kidney
cold and asthenia, edema, tinnitus, spermatorrhea, impotence,
stomach diseases, dyspepsia, and other diseases, and this
preparation has been approved by the State Administration of
Traditional Chinese Medicine of the People’s Republic of China
(http://www.sfda.gov.cn, 2014; (Si and Liu, 2013); Table 1).
Meanwhile, Wu et al. (2014) reported that in clinical practice of
Mongolian medicine, after administrating orally two Shenzhujin
pills (the tuber is the primary component) for three times per day
for 21 days, the kidney deficiency of one patient (65 years) have
been cured.
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TABLE 1 | Preparations in which Gymnadenia conopsea (L.) R. Br. was the primary component as listed in the Chinese Pharmacopeia and approved by
the government*.
Preparation name Main compositions Usage
Shi Wei Shou Shen San Tuber Gymnadenia, Cinnamomi Cortex, Myristicae Semen, Piperis Longi
Fructus, Asparagi Radix, Granati Pericarpium, Canavaliae Semen,
Carthami Flos, Moschus, Bear Gall.
Invigorating the kidney and treating spermatorrhea.
Fu Fang Shou Shen Wan Tuber Gymnadenia, Polygonati Rhizoma, Cynomorii Herba, Chebulae
Fructus, Rhizoma Mirabilis Himalaica, Asparagi Radix, Cordyceps,
Tribuli Fructus, Rhizoma Przewalskia Tangutica, Herba Pleurospermum.
Warming the kidney and activating yang. Treating
insufficiency of kidney-YANG, damage of essence,
impotence, and spermatorrhea, etc.
Shou Shen Shen Bao Jiao Nang Tuber Gymnadenia, Polygonati Rhizoma, Asparagi Radix, Folium
Rhododendron Anthopogonoides, Cordyceps.
Warming the kidney and invigorating yin. Treating
giddy dazzled, tinnitus, lumbar genu aching, and
limp is faint induced by kidney asthenia.
Shou Zhang Shen 37 Wan Tuber Gymnadenia, Calcite, Alpiniae Oxyphyliae Fructus, Granati
Pericarpium, Zingiberis Rhizoma, Feces Trogopterori, Myristicae Semen,
Piperis Longi Fructus, Gecko, Chebulae Fructus, Sal Ammoniac, Folium
Rhododendron Anthopogonoides, etc.
Invigorating the kidney and strengthening yang.
Treating kidney asthenia, edema, tinnitus,
impotence, and spermatorrhea, etc.
Fu Fang Shou Shen Yi Zhi Jiao Nang Tuber Gymnadenia, Polygoni Multiflori Radix Praeparata,
Acanthopanacis Senticosi Radix, Polygonati Rhizoma, Angelicae
Sinensis Radix, Asteragali Radix, Lycii Fructus, Schisandrae Chinensis
Fructus, Corni Fructus, Rhizoma Polygala, Acori Tatarinowii Rhizoma,
Paeoniae Radix Rubra.
Invigorating the kidney and liver, and treating the
deficiency of liver and kidney, amnesia, palpitation,
and insomnia induced by Qi and blood
hemophthisis.
*Cited from “Chinese Pharmacopeia” and the Website: http://www.sfda.gov.cn.
Furthermore, the tuber of G. conopsea is also used in Korean
national medicine, Bai national medicine, and Naxi national
medicine, where it is known as Yinyang Cao, Foshousheng,
and Kaishelabei, respectively. However, it has been used as a
reinforcing agent within all of these traditional medicines and
used to treat similar diseases as previously indicated, such as
invigorating the body, strengthening the Yang, etc. (Jia and
Li, 2005). But up to now, except the experience-based uses
of this plant, the relevant evidence-based clinical uses and the
safety data scientifically are very rare and should be investigated
further.
PHYTOCHEMISTRY
Approximately 129 compounds have been isolated and
identified from G. conopsea to date, and most of compounds
isolated from the tuber. Forty-nine glucosides compounds
(one of the most important components) were identified,
which could be divided into benzylester glucosides and other
glucosides. Meanwhile, dihydrostilbenes, phenanthrenes,
aromatic compounds, polysaccharides, and other compounds
were also isolated and reported (Table 2; Figure 2). The different
chemical compositions of G. conopsea provide the foundation
for its different pharmacology activities.
Glucosides
As one of the most important components, glucosides are widely
studied and separated from the tuber of G. conopsea. According
to the structural conformation of the glucosides, they have been
divided into benzylester glucosides and other glucosides.
Benzylester Glucosides
Benzylester glucosides are produced by combining 2-
isobutyl tartaric acid or 2-isobutyl hydroxysuccinic acid
with 4-glycosylbenzyl alcohol. According to the differences in
their organic acids, they are classified as (2R, 3S)-2-isobutyl
tartaric acid derivates and (2R)-2-isobutyl hydroxysuccinic
acid derivatives. Approximately 29 compounds have been
isolated and identified. In 2006, Morikawa et al. (2006a,b)
isolated the following compounds: gymnoside I (1), gymnoside
II (2), gymnoside III (3), gymnoside IV (4), gymnoside
V (5), gymnoside VI (6), gymnoside VII (7), gymnoside
VIII (8), gymnoside IX (9), gymnoside X (10), loroglossin
(11), dactylorhin A (12), dactylorhin B (13)and militarine
(14). Meanwhile, (−)-4-[β-D-glucopyranosyl-(1→4)-
β-D-glucopyranosyloxy] benzyl alcohol (15), (+)-4-[α-
D-glucopyranosyl-(1→4)-β-D-glucopyranosyloxy] benzyl
alcohol (16), (−)-4-[β-D-glucopyranosyl-(1→3)-β-D-
glucopyranosyloxy] benzyl alcohol (17), (−)-4-[β-D-
glucopyranosyl-(1→3)-β-D-glucopyranosyloxy] benzyl ethyl
ether (18), (−)-(2R,3S)-1-(4-β-D-glucopyranosyloxybenzyl)-2-
O-β-D-glucopyranosy]-4-{4-[α-D-glucopyranosyl-(1→4)-β-D-
glucopyranosyloxy]benzyl}-2-isobutyltartrate (19), (−)-(2R,3S)-
1-(4-β-D-glucopyranosyloxybenzyl)-2-O-β-D-glucopyranosyl-4
-{4-[β-D-glucopyranosyl-(1→3)-β-D-glucopyranosyloxy] benzy
l}-2-isobutyltartrate (20), (−)-(2R,3S)-1-{4-[β-D-glucopyranosy
l-(1→3)-β-D-glucopyranosyloxy]benzyl}-2-O-β-D-glucopyrano
syl-4-(4-β-D-glucopyranosyloxybenzyl)-2-isobutyl-tartrate (21),
(−)-(2R,3S)-1-(4-β-D-glucopyranosyloxybenzyl)-4-{4-[β-D-glu
copyranosyl-(1→6)-β-D-glucopyranosyloxy]benzyl}-2-isobutyl
tartrate (22), (−)-(2R,3S)-1-(4-β-D-glucopyranosyloxybenzyl)-
4-methyl-2-isobutyltartrate (23) and (−)-(2R)-2-O-β-D-glu
copyranosyl-4-(4-β-D-glucopyranosylbenzyl)-2-isobutyltartrate
(24) were isolated from the tuber in 2008. And the further
studies showed that at 10−5 M, the inhibition rates of the
above compounds foracetylcholine esterase were <10%, and the
positive drug donepezil gave an inhibition rate of 77.2%. Then,
the results presented that at 10−5 M, the inhibition rates of the
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TABLE 2 | Compounds isolated from Gymnadenia conopsea (L.) R. Br. (the structure of the primary compounds are illustrated in Figure 2).
No. Names Parts References
1 Gymnoside I Tuber Morikawa et al., 2006a
2 Gymnoside II Tuber Morikawa et al., 2006a
3 Gymnoside III Tuber Morikawa et al., 2006a
4 Gymnoside IV Tuber Morikawa et al., 2006a
5 Gymnoside V Tuber Morikawa et al., 2006a
6 Gymnoside VI Tuber Morikawa et al., 2006a
7 Gymnoside VII Tuber Morikawa et al., 2006a
8 Gymnoside VIII Tuber Morikawa et al., 2006b
9 Gymnoside IX Tuber Morikawa et al., 2006b
10 Gymnoside X Tuber Morikawa et al., 2006b
11 Loroglossin Tuber Morikawa et al., 2006b
12 Dactylorhin A Tuber Morikawa et al., 2006b
13 Dactylorhin B Tuber Morikawa et al., 2006b
14 Militarine Tuber Morikawa et al., 2006b
15 (−)-4-[β-D-glucopyranosyl-(1→4)-β-D-glucopyranosyloxy] benzyl alcohol Tuber Zi, 2008; Zi et al., 2008
16 (+)-4-[α-D-glucopyranosyl-(1→4)-β-D-glucopyranosyloxy] benzyl alcohol Tuber Zi, 2008; Zi et al., 2008
17 (−)-4-[β-D-glucopyranosyl-(1→3)-β-D-glucopyranosyloxy] benzyl alcohol Tuber Zi, 2008; Zi et al., 2008
18 (−)-4-[β-D-glucopyranosyl-(1→3)-β-D-glucopyranosyloxy] benzyl ethyl ether Tuber Zi, 2008; Zi et al., 2008
19 (−)-(2R,3S)-1-(4-β-D-glucopyranosyloxybenzyl)-2-O-β-D-glucopyranosy]-4-{4-[α-D-glucopyranosyl-
(1→4)-β-D-glucopyranosyloxy]benzyl}-2-isobutyltartrate
Tuber Zi, 2008; Zi et al., 2008
20 (−)-(2R,3S)-1-(4-β-D-glucopyranosyloxybenzyl)-2-O-β-D-glucopyranosyl-4-{4-[β-D-glucopyranosyl-
(1→3)-β-D-glucopyranosyloxy]benzyl}-2-isobutyltartrate
Tuber Zi, 2008; Zi et al., 2008
21 (−)-(2R,3S)-1-{4-[β-D-glucopyranosyl-(1→3)-β-D-glucopyranosyloxy]
benzyl}-2-O-β-D-glucopyranosyl-4-(4-β-D-glucopyranosyloxybenzyl)-2-isobutyltartrate
Tuber Zi, 2008; Zi et al., 2008
22 (−)-(2R,3S)-1-(4-β-D-glucopyranosyloxybenzyl)-4-{4-[β-D-glucopyranosyl-(1→6)-β-D-
glucopyranosyloxy]benzyl}-2-isobutyltartrate
Tuber Zi, 2008; Zi et al., 2008
23 (−)-(2R,3S)-1-(4-β-D-glucopyranosyloxybenzyl)-4-methyl-2-isobutyltartrate Tuber Zi, 2008; Zi et al., 2008
24 (−)-(2R)-2-O-β-D-glucopyranosyl-4-(4-β-D-glucopyranosylbenzyl)-2-isobutyltartrate Tuber Zi, 2008; Zi et al., 2008
25 Dactylorhin E Tuber Zi, 2008
26 Coelovirins A Tuber Zi, 2008
27 Coelovirins B Tuber Zi, 2008
28 Coelovirins D Tuber Zi, 2008
29 Coelovirins E Tuber Zi, 2008
30 4-Hydroxybenzyl-β-D-glucopyranoside Tuber Yang, 2009
31 4-Methylphenyl-β-D-glucopyranoside Tuber Yang, 2009
32 4-Hydroxyphenyl-β-D-glucopyranoside Tuber Yang, 2009
33 4-Methoxymethylbenzyl-β-D-glucoside Tuber Morikawa et al., 2006b
34 bis (4-hydroxybenzyl)-ethermono-β-D-glucopyranoside Tuber Morikawa et al., 2006b
35 4-(β-D-glucopyranosyloxy) benzoic aldehyde Tuber Zi, 2008
36 4-(β-D-glucopyranosyloxy) benzyl ethyl ether Tuber Zi, 2008
37 Phenyl-β-D-glucopyranoside Tuber Morikawa et al., 2006b
38 4-Formylphenyl-β-D-glucopyranoside Tuber Morikawa et al., 2006b
39 Benzyl-β-D-glucopyranoside Tuber Morikawa et al., 2006b
40 trans-ferulic acid-β-D-glucoside Tuber Zi, 2008
41 cis-ferulic acid-β-D-glucoside Tuber Zi, 2008
42 N6-(4-hydroxybenzyl) adenine riboside Tuber Zi, 2008
43 Daucosterol Tuber Li et al., 2007
44 Dioscin Tuber Li et al., 2001
45 Dactylose A Tuber Morikawa et al., 2006b
46 Dactylose B Tuber Morikawa et al., 2006b
47 n-Butyl-β-D-fructopyranose Tuber Li et al., 2001
(Continued)
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TABLE 2 | Continued
No. Names Parts References
48 Thymidine Tuber Morikawa et al., 2006b
49 Batatasin III Tuber Matsuda et al., 2004
50 3′-O-methylbatatasin III Tuber Matsuda et al., 2004
51 3′,5-Dihydroxy-2-(4-hydroxybenzyl)-3-methoxybibenzyl Tuber Matsuda et al., 2004
52 3,3′-Dihydroxy-2-(4-hydroxybenzyl)-5-methoxybibenzyl Tuber Matsuda et al., 2004
53 Gymconopin D Tuber Matsuda et al., 2004
54 3,3′-Dihydroxy-2,6-bis(4-hydroxybenzyl)-5-methoxybibenzyl Tuber Matsuda et al., 2004
55 5-O-methylbatatacin III Tuber Yoshikawa et al., 2005
56 2-(4-Hydroxybenzyl)-3′-O-methylbatatacin III Tuber Yoshikawa et al., 2005
57 Arundinin Tuber Yoshikawa et al., 2005
58 Arundin Tuber Yoshikawa et al., 2005
59 Bulbocodin C Tuber Yoshikawa et al., 2005
60 Bulbocodin D Tuber Yoshikawa et al., 2005
61 Gymconopin A Tuber Matsuda et al., 2004
62 Gymconopin B Tuber Yoshikawa et al., 2005
63 Gymconopin C Tuber Yoshikawa et al., 2005
64 1-(4-Hydroxybenzyl)-4-methoxy-9,10-dihydrophenanthrene-2,7-diol Tuber Matsuda et al., 2004
65 1-(4-Hydroxybenzyl)-4-methoxyphenanthrene-2,7-diol Tuber Matsuda et al., 2004
66 Dihydrophenanthrene-4,5-diol Tuber Matsuda et al., 2004
67 2-Methoxy-9,10-4-methoxy-9,10-dihydrophenanthrene-2,7-diol Tuber Matsuda et al., 2004
68 Blestriarene A Tuber Matsuda et al., 2004
69 Blestriarene A Tuber Matsuda et al., 2004
70 Blestriarene A Tuber Matsuda et al., 2004
71 9, 10-Dihydro blestriarene B Tuber Matsuda et al., 2004
72 9,10–9′,10′-Dihydro blestriarene C Tuber Matsuda et al., 2004
73 4-Hydroxybenzyl alcohol Tuber Cai et al., 2006
74 4-Hydroxybenzyl aldehyde Tuber Cai et al., 2006
75 Pinoresinol Tuber Morikawa et al., 2006b
76 4-Hydroxybenzoic acid Tuber Yue et al., 2010
77 Vanillic acid Tuber Yue et al., 2010
78 Trans-p-coumaric acid Tuber Yue et al., 2010
79 Cis-p-coumaric acid Tuber Yue et al., 2010
80 4-Benzaldehyde Tuber Morikawa et al., 2006b
81 4-Hydroxybenzyl methyl ether Tuber Zi, 2008
82 3,5-Methoxy benzaldehyde Tuber Morikawa et al., 2006b
83 4-[(4-Hydroxyphenyl)methoxy]-benzenemethanol Tuber Morikawa et al., 2006b
84 4,4′-Dihydroxydiphenyl methane Tuber Morikawa et al., 2006b
85 Phenol Tuber Morikawa et al., 2006b
86 5-Hydroxymethyl furfural Tuber Morikawa et al., 2006b
87 1,2-Dihydroxy benzene Tuber Morikawa et al., 2006b
88 2,6-Dimethoxy phenol Tuber Morikawa et al., 2006b
89 Eugenol Tuber Morikawa et al., 2006b
90 4-Hydroxybenzene Tuber Morikawa et al., 2006b
91 4-Methoxy phenylpropanol Tuber Morikawa et al., 2006b
92 4-Ethoxy phenylpropanol Tuber Morikawa et al., 2006b
93 Contra-hydroxybenzyl dithioether Tuber Morikawa et al., 2006b
94 Syringol Tuber Morikawa et al., 2006b
95 Syringaldehyde Tuber Morikawa et al., 2006b
96 Gastrodin Tuber Yue et al., 2010
97 4-Hydroxybenzoic aldehydes Tuber Zi, 2008
98 4-Hydroxybenzoic acid Tuber Yue et al., 2010
(Continued)
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TABLE 2 | Continued
No. Names Parts References
99 3-Hydroxybenzoic acid Tuber Yue et al., 2010
100 4-Hydroxyisophthalic acid Tuber Yue et al., 2010
101 3-Methoxy-4-hydroxybenzoic acid Tuber Yue et al., 2010
102 Arctigenin Tuber Yue et al., 2010
103 erythro-buddlenol E Tuber Zi, 2008
104 Lappaol A Tuber Yue et al., 2010
105 Lappaol F Tuber Yue et al., 2010
106 2-Hydroxy-2-(4-hydroxyphenylmethyl)-4-methylcyclopent-4-en-1,3-dione Tuber Zi, 2008
107 2-Hydroxy-3-(4-hydroxyphenyl)-4-hydroxymethylcyclopent-2-enone Tuber Zi, 2008
108 3,3′-Dihydroxy-4-(4-hydroxybenzyl)-5-methoxybibenzyl Tuber Morikawa et al., 2006b
109 2-C-(4-hydroxybenzyl)-α-L-xylo-3-ketohexulofuranosono-1,4-lactone Tuber Morikawa et al., 2006b
110 Arabinose Tuber Sun et al., 2010
111 Xylose Tuber Sun et al., 2010
112 Mannitose Tuber Sun et al., 2010
113 Galactose Tuber Sun et al., 2010
114 Glucose Tuber Sun et al., 2010
115 Secoxyloganin Tuber Zi, 2008
116 Quercitin-3, 7-di-O-β-D-glucopyranoside Tuber Zi, 2008
117 Kaempferol-3-β-glycosido-7-β-glycoside Flower Schonsiegel and Ingomar, 1969
118 Quercetin-3-β-glycosido-7-glycoside Flower Schonsiegel and Ingomar, 1969
119 Astragalin Flower Schonsiegel and Ingomar, 1969
120 Isoquercetin Flower Schonsiegel and Ingomar, 1969
121 Cyclo(L-Leu-L-Tyr) Tuber Zi, 2008
122 Cyclo(L-Leu-L-Pro) Tuber Zi, 2008
123 Cyclo(L-Val-L-Tyr) Tuber Zi, 2008
124 Cyclo(L-Ala-L-Phe) Tuber Zi, 2008
125 Thymidine Tuber Yue et al., 2010
126 β-sitoterol Tuber Yue et al., 2010
127 Octadecylselyl acid Tuber Yue et al., 2010
128 Di-(p-hydroxybenzyl) disulfide Tuber Li et al., 2007
129 4.4′-Dihydroxybenzyl sulfoxide Tuber Li et al., 2007
above compounds formonoamine oxidase-B were <15.2%, and
the positive drug pargyline had an inhibition rate of 94.5% (Zi
et al., 2008). Meanwhile, dactylorhin E (25), coelovirins A (26),
coelovirins B (27), coelovirins D (28), and coelovirins E (29) also
were isolated (Zi, 2008).
Other Glucosides
Other glucosides have also been isolated from the tuber of
G. conopsea. In 2009, Yang identified 4-hydroxybenzyl-β-D-
glucopyranoside (30), 4-methylphenyl-β-D-glucopyranoside
(31), and 4-hydroxyphenyl-β-D-glucopyranoside (32). The
following compounds have also been isolated (Li et al., 2001;
Morikawa et al., 2006b; Zi, 2008): 4-methoxymethylbenzyl-
β-D-glucoside (33), bis (4-hydroxybenzyl)-ether mono-β-D-
glucopyranoside (34), 4-(β-D-glucopyranosyloxy) benzoic
aldehyde (35), 4-(β-D-glucopyranosyloxy)benzyl ethyl ether
(36), phenyl-β-D-glucopyranoside (37), 4-formylphenyl-
β-D-glucopyranoside (38), benzyl-β-D-glucopyranoside
(39), trans-ferulic acid-β-D-glucoside (40), cis-ferulic
acid-β-D-glucoside (41), N6-(4-hydroxybenzyl)adenine
riboside (42), daucosterol (43), dioscin (44), dactylose A
(45), dactylose B (46), n-butyl-β-D-fructopyranose (47), and
thymidine (48).
Dihydrostilbenes
Dihydrostilbenes are other important components of G.
conopsea. The basic parental nucleus of these compounds is
dihydrogen alkene. The C-2, -3, -4, -5, -6 and -3′ positions
of the basic nucleus areusually substituted. In 2004 and
2005, batatacin III (49), 3′-O-methylbatatacin III (50), 3′,5-
dihydroxy-2-(4-hydroxybenzyl)-3-methoxybibenzyl (51),
3,3′-dihydroxy-2-(4-hydroxybenzyl)-5-methoxybibenzyl (52),
gymconopin D (53), 3,3′-dihydroxy-2,6-bis(4-hydroxybenzyl)-
5-methoxybibenzyl (54), 5-O-methylbatatacin III (55),
2-(4-hydroxybenzyl)-3′-O-methylbatatacin III (56), arundinin
(57), arundin (58), bulbocodin C (59), bulbocodin D (60) were
isolated and identified from the tuber, respectively (Matsuda
et al., 2004; Yoshikawa et al., 2005).
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FIGURE 2 | Chemical structures of the primary compounds from the tuber of Gymnadenia conopsea (L.) R. Br.
Phenanthrenes
A group of phenanthrene compounds was isolated from the
tuber of G. conopsea and studied in recent decades, including
gymconopin A (61), gymconopin B (62), gymconopin C (63),
1-(4-hydroxybenzyl)-4-methoxy-9,10-dihydrophenanthrene-2,7-
diol (64), 1-(4-hydroxybenzyl)-4-methoxyphenanthrene-2,7-diol
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(65), 2-methoxy-9,10-dihydrophenanthrene-4,5-diol (66), 4-
methoxy-9,10-dihydrophenanthrene-2,7-diol (67), blestriarene
A (68), blestriarene A (69), blestriarene A (70), 9, 10-dihydro
blestriarene B (71), and 9,10–9′,10′-dihydro blestriarene C (72)
(Matsuda et al., 2004; Yoshikawa et al., 2005).
Aromatic Compounds
Approximately 20 aromatic compounds from G. conopsea have
been studied, and most of them are phenol compounds. In
2006, Cai et al. (2006) isolated 4-hydroxybenzyl alcohol (73)
and 4-hydroxybenzyl aldehyde (74) from the tuber. Then,
pinoresinol (75), 4-hydroxybenzoic acid (76), vanillic acid
(77), trans-p-coumaric acid (78), cis-p-coumaric acid (79),
4-benzaldehyde (80), 4-hydroxybenzyl methyl ether (81), 3,5-
methoxy benzaldehyde (82), 4-[(4-hydroxyphenyl)methoxy]-
benzenemethanol (83), 4,4′-dihydroxydiphenyl methane
(84), phenol (85), 5-hydroxymethyl furfural (86), 1,2-
dihydroxybenzene (87), 2,6-dimethoxy phenol (88), eugenol
(89), 4-hydroxybenzene (90), 4-methoxy phenylpropanol
(91), 4-ethoxy phenylpropanol (92), contra-hydroxybenzyl
dithioether (93), syringol (94), syringaldehyde (95), gastrodin
(96), 4-hydroxybenzoic aldehydes (97), 4-hydroxybenzoic acid
(98), 3-hydroxybenzoic acid (99), 4-hydroxyisophthalic
acid (100), 3-methoxy-4-hydroxybenzoic acid (101),
arctigenin (102), erythro-buddlenol E (103), lappaol A (104),
lappaol F (105), 2-hydroxy-2-(4-hydroxyphenylmethyl)-
4-methylcyclopent-4-en-1,3-dione (106), 2-hydroxy-3-(4-
hydroxyphenyl)-4-hydroxymethylcyclopent-2-enone (107),
3,3′-dihydroxy-4-(4-hydroxybenzyl)-5-methoxybibenzyl (108),
and 2-c-(4-hydroxybenzyl)-α-L-xylo-3-ketohexulofuranosono-
1,4-lactone (109) were isolated and identified from the tuber of
G. conopsea (Morikawa et al., 2006b; Zi, 2008; Yue et al., 2010).
Polysaccharides
In 2009, Yang (2009) studied the four extraction and purification
methods for the polysaccharides of G. conopsea. The results
showed that the optimum parameters for solvent extraction
were 80◦C for 2.5 h, a ratio of material to water of 1:30
with three repetitions, which yielded a polysaccharide extraction
rate of up to 11.83%. The microwave extraction method were
250 W for 20min, a ratio of material to water of 1:30 with
one repetition, and the extraction rate was up to 13.56%. The
ultrasound extraction method was 240 W, 60◦C for 10min, and
three repetitions, and the extraction rate was 15.24%. Finally,
the parameters for cellulose extraction were to add cellulose
at 1% of the tuber concentration for 4 h at 50◦C and Ph 4.8,
and the extraction rate was 16.58%. Thus, the cellulose method
is the best among the four methods. Meanwhile, vapor phase
chromatography was adopted to analyze the monosaccharides
from the polysaccharides, and the results showed that the
polysaccharides are composed of arabinose (110), xylose (111),
mannitose (112), galactose (113), and glucose (114) (Sun
et al., 2010). And in 2014, the water soluble polysaccharides
from the tuber of G. conopsea collected at seven regions in
China were investigated and compared using high performance
size exclusion chromatography coupled with multi-angle laser
light scattering/refractive index detector (HPSEC-MALLS/RID)
and saccharide mapping based on polysaccharide analysis
by carbohydrate gel electrophoresis (PACE), respectively. The
results showed that the weight-average molecular weight (Mw)
and the radius of gyration (<S2>z1/2) of polysaccharides were
ranging from 4.46 × 105 to 7.41 × 105 Da and 73.3–94.2 nm,
respectively. And the exponent (v) values of <S2>z1/2 = kMvw
were ranging from 0.36 to 0.42, which indicated that α-1,4-
and β-1,3(4)-glucosidic, α-1,5-arabinosidic, β-1,4-mannosidic
and α-1,4-D-galactosiduronic linkages existed in globular
polysaccharides. The further studies results that the nitric oxide
released from RAW 264.7 cells induced by polysaccharides
were significantly affected by their α-1,5-arabinosidic and β-
1,3(4)-glucosidic, especially α-1,4-D-galactosiduronic and β-1,4-
mannosidic linkages (Lin et al., 2015).
Other Compounds
From G. conopsea, six flavones were isolated from the
flower, including secoxyloganin (115), quercitin-3, 7-di-O-β-D-
glucopyranoside (116), kaempferol-3-β-glycosido-7-β-glycoside
(117), and quercetin-3-β-glycoside-7-glycoside (118), astragalin
(119) and isoquercetin (120) (Schonsiegel and Ingomar, 1969;
Zi, 2008). Then, cyclo(L-Leu-L-Tyr) (121), cyclo(L-Leu-L-
Pro) (122), cyclo(L-Val-L-Tyr) (123), cyclo(L-Ala-L-Phe) (124),
thymidine (125), β-sitoterol (126), and octadecylselyl acid
(127) were isolated (Yue et al., 2010; Zi et al., 2010). And
di-(p-hydroxybenzyl) disulfide (128) and 4.4′-dihydroxybenzyl
sulfoxide (129) also were identified (Li et al., 2007). Lan
(2005) determined the trace element contents of the tuber of
Gymnadenia conopsea (L.) R. Br., and the results showed that the
Cu, Mn, Fe, Zn, Ni, Se, Cr, K, Ca, Mg, Cd, and Pb contents in
µg/g were 7.6, 31.6, 60.3, 20.1, 2.1, 6.0, 2.0, 19,000, 4100, 1800,
0.16, and 3.31, respectively.
PHARMACOLOGY
Tonifying Effect and Anti-Fatigue Activity
In China, the G. conopsea tuber has been used as a reinforcing
agent for traditional medicines, and it has historically been used
to treat kidney asthenia, lung asthenia, consumption diseases,
neurasthenia, impotence, spermatorrhea, and other diseases.
According to the theory of traditional Chinese medicine, kidney
asthenia is related to weakness in the body. Thus, the tonifying
activity (kidney-yang-tonifying activity) was the primary subject
of study in China. The results showed that after administering
orally 2 and 1 g/kg the tuber for 10 days, the medicine relieved the
symptoms in mice with yang deficiencies that had been induced
by hydrocortisone (25mg/kg, i.g.), increased the body weight of
kidney-yang-deficientmice (7.82 and 5.56 g, P> 0.05), prolonged
the retention time on the rotating bar (19.57 ± 10.21 min, P <
0.01, and 5.90 ± 2.47min, P < 0.05) and increased the kidney
indexes of treated mice compared with those of the model group.
And the increased weight and time on the rotating bar for the
untreated control groups were 8.71 g (P > 0.05) and 24.20 ±
13.95 min (P < 0.01), respectively. Further, study showed that
the tubers could also increase DNA synthesis in the spleen (48.89
± 18.68 and 46.63 ± 13.80 µg/g, P < 0.01), kidneys (14.26 ±
5.34 and 5.94 ± 4.88 µg/g, P > 0.05), and liver (42.94 ± 13.95
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µg/g and 42.02± 17.69, P < 0.05) of mice with yang deficiencies
that were induced by hydrocortisone compared with the mice
in the model group (27.25 ± 13.18 µg/g, P < 0.01, 4.90 ± 4.82
µg/g, P> 0.05, and 19.02± 15.49 µg/g). These results suggested
that the tuber has a significant tonifying effect on the kidney and
strengthens the bodies of mice with kidney deficiencies that were
induced by hydrocortisone (Lin, 2009).
In 2011, Zhao and Liu (2011) studied the anti-fatigue activity
of the tuber of G. conopsea in mice. After administering orally
(i.g.) aqueous extracts to mice (40, 20, and 10 g/kg) for 6 days,
the swimming times were markedly increased (1441.6, 1357.0,
and 1249.9 s, P < 0.01) during the weight-bearing swimming
tests in a dose-dependent manner. The swimming times of the
control and positive groups (Radix ginseng, 20 g/kg) were 491.1 s
and 1685.9 s (P < 0.01). According to the processing method
of traditional Mongolia medicine in China, the tuber should be
decocted in goat or cow milk before clinical use. After processing
with a different method, Jin and Wang (2009) studied and
compared the strengthening effects of the tuber of G. conopsea
tonics. The results showed that compared with the control group
(saline water, 6.38± 4.22min), a goat milk decoction (2 g/kg. i.g.)
could significantly increase the swimming time of mice (19.44 ±
12.6min, P < 0.01); the unprocessed group (2 g/kg) and cow’s
milk decoction group (2 g/kg) had swimming times of 9.09 ±
9.81min and 6.43 ± 7.21min (P > 0.05), respectively, but they
did not show significant difference. All of the decoctions could
increase the SOD activity and MDA content compared with that
of the control group. Thus, the researchers indicated that after
processing with goat milk, the tuber have a better effect with the
strengthening tonics than unprocessed medicine (Table 4).
Anti-Oxidant Activity
The anti-oxidant activity of the tuber of G. conopsea was
first comprehensive studied in 2006. The results showed
that after isolating by Diaion HP-20 column chromatography
(reverse-phase silica gel columnchromatography, Chromatorex
ODSDM1020T, 100–200 mesh, Fuji Silysia Chemical, Ltd.), the
MeOH-eluted fraction showed the radical scavenging activities
for DPPH radical (SC50 = 59.1 µg/ml) and.O
−
2 (IC50 =
13.3 µg/ml), but without the inhibitory activity on xanthine
oxidase (IC50 > 100 µg/ml). Meanwhile, the radical scavenging
activities for DPPH radical and.O−2 exhibiting inhibitory activity
on formozan formation and xanthine oxidase of the acetone-
eluted fraction were 55.4, 33.2, and 29.7 µg/ml, respectively.
But H2O-eluted fraction didn’t present any activities. Then,
the anti-oxidant 13 compounds were studied further, some
compounds showed the marked radical scavenging activities for
DPPH radical and.O−2 exhibiting inhibitory activity on formozan
formation and xanthine oxidase of 13 compounds (Morikawa
et al., 2006b; Table 3). Meanwhile, the study simultaneously
showed that at a concentration of 10−6 mol/L, arctigenin, lappaol
A, and lappaol F have anti-oxidative activities that inhibit Fe2+-
cystine-induced lipid peroxidation in rat liver microsomes with
inhibitory rates of 53, 59, and 52%, respectively, relative to that of
vitamin E at 35% (Zi et al., 2008).
In 2010, Li et al. (2010) screened and evaluated the aqueous
extract, acidic aqueous extract (pH = 3), 60% ethanol extract,
95% ethanol extract, n-butanol extract, n-butanol saturated
by aqueous extract and ethyl acetate extracts of the tuber of
G. conopsea for their radical scavenging capacity. The results
showed that the radical scavenging capacity of the aqueous
and acidic aqueous (pH = 3) extracts were weak. The radical
scavenging activities (IC50) of the other extracts were 0.1266,
0.4537, 0.3151, and 0.1305mg /ml. Thus, the investigators
indicated that the 95% ethanol extract was the most effective
among the six extracts (Table 4).
Anti-Viral Activity
In 2008, Zi (2008) studied the anti-HIV activity of certain
compounds from the tuber of G. conopsea at a concentration
of 10−5mol/L in relation to the drugs zidovudine (10−7mol/L,
85.6%) and lamivudine (10−8mol/L, 47.4%), and the inhibition
rates of these compounds against the VSVC/HIV-luc model in
293 cell lines were 0.6–13.3% (Table 3).
In Tibet, G. conopsea has primarily been used by local
people to treat chronic hepatitis B. In 2002, Lu et al. (2002)
studied the anti-HBV activity. The results showed that after
treating the patient’s serum that contained hepatitis B for 4 h,
the medicine (0.03, 0.06, and 0.12mg/L) could inhibit eight
hemagglutin units of HBsAg. Thus, they indicated that the tuber
has medium anti-HBV activity. In 2003, Kimura et al. (2003)
studied the inhibitory effect of Tibetan medicinal plants on viral
polymerases. The results showed that at 100 µg/ml, 28 species
of 76 medicines presented the anti-RTase activity with the more
than 70% inhibition rates. But after adding BSA to these drugs,
except the fruit of Terminalia chebula and Areca catechu, other
species didn’t show the anti-RTase activity, including G. conopsea
(Kimura et al., 2003; Table 4).
Sedative and Hypnotic Activities
In 2009, Lin (2009) studied the sedative and hypnotic effects
of the tuber of Gymnadeniae tubers at different dosages. In
the sedative test, administering the tuber (2 and 1 g/kg i.g.)
for 30min, it could reduce the spontaneous activity of mice
within 5min (6.63 ± 3.18 and 5.36 ± 3.44) at inhibitory rates
of 37.44% (P < 0.05) and 45.60% (P < 0.05), and the control
group (normal saline) and positive group (diazepam, 0.004 g/kg)
exhibited inhibition of 10.60 ± 5.77 and 3.66 ± 1.47 (an
inhibition of 64.21%, P < 0.01), respectively. The tubers could
also decrease the frequency of upward-raising motion in mice
forelimbs within 5min, especially for the high dose group at 15.42
± 11.77 times (P < 0.05). The upward-raising frequency of the
control and positive groups were 22.11 ± 6.92 and 9.37 ± 3.65
(P< 0.01), respectively.
In the mesmerism test, the medicine could prolong sleeping
times at doses of 2 and 1 g/kg i.g. (32.94 ± 14.84min, P < 0.01;
and 28.85 ± 11.28min, P < 0.05, respectively) in mice and
decrease the latency time (3.00 ± 0.82min, and 3.34 ± 0.52
min, P > 0.05, respectively) induced by pentobarbital sodium
over the threshold dose (50mg/kg) compared with mice in
the control group (13.96 ± 8.45 and 4.80 ± 1.85min); the
positive groups were 45.31 ± 12.31min (P < 0.01) and 1.05
± 0.31 min (P < 0.05). This treatment also increased the
number of sleeping mice (18 and 18) and latency time (3.11 ±
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TABLE 3 | Activities of specific compounds from Gymnadenia conopsea (L.) R. Br.
Compounds Effects In vitro test References
Gymconopin A Anti-oxidant
activity
Radical scavenging activities for DPPH radical and.O−2 exhibiting
inhibitory activity on formozan formation and xanthine oxidase at
29.2, 45.8, and >100 µM; 33.4, 21.5, and >100 µM; 31.2 µM,
>100 µM and null; 12.7, 0.95, and 44.0 µM; 8.2, 0.19, and 30.5
µM; 15.7, 9.4, and >100 µM; 5.8, 0.27, and 4.5 µM; >40, 82.8,
and >100 µM; >40, 9.3, and 72.9 µM; >40, 13.4, and 45.1 µM;
>40, 13.4, and 65.2 µM; 11.0, null and null; 6.0, 1.5, and >10
µM, respectively.
Morikawa et al., 2006b
GymconopinB
2-Methoxy-9,10-dihydrophenanthrene-4,5-diol
4-Methoxy-9,10-dihydrophenanthrene-2,7-diol
1-(4-Hydroxybenzyl)-4-methoxy-9,10-
dihydrophenanthrene-2,7-diol
1-(4-Hydroxybenzyl)-4-methoxyphenanthrene-
2,7-diol
Blestriarene A
BatatacinIII 3′,5-Dihydroxy-2-(4-hydroxybenzyl)-3-
methoxybibenzyl3,3′-Dihydroxy-2-(4-
hydroxybenzyl)-5-methoxybibenzyl
3,3′-Dihydroxy-2,6-bis-(4-hydroxybenzyl)-5-
methoxybibenzyl
α-Tocopherol
(+)-Catechin
Arctigenin
Lappaol A
Lappaol F
Anti-oxidant
activity
Anti-oxidative activity inhibiting Fe2+-cystine activity induced in rat
liver microsomal lipid peroxidation with inhibitory rates of 53, 59,
and 52%, compared with that of vitamin E at 35%.
Zi et al., 2008
(−)-4-[β-D-glucopyranosyl-(1→4)-β-D-
glucopyranosyloxy]benzyl
alcohol(−)-4-[β-D-glucopyranosyl-(1→3)-β-D-
glucopyranosyloxy] benzyl ethyl
ether(−)-(2R,3S)-1-[4-β-D-
glucopyranosyloxybenzyl]-4-methyl-2-
isobutyltartrate
Anti-HIV activity At a concentration of 10−5 mol/L, the inhibition rates of these
compounds against VSVC/HIV-luc model in 293 cell lines were
9.0, 5.0, 6.2, 11.9, 11.3, 0.6, 13.3, 5.1, 10.0, 2.4, and 0.6%,
respectively. Comparisons with the positive drugs zidovudine
(10−7 mol/L, 85.6%) and lamivudine (10−8 mol/L, 47.4%) were
performed.
Zi, 2008
Cyclo[gly-L-S-(4-hydroxybenzyl)]cys
2-Hydroxy-2-(4-hydroxyphenylmethyl)-4-
methylcyclopent-4-en-1,3-dione
2-Hydroxy-3-(4-hydroxyphenyl)-4-
hydroxymethylcyclopent-2-enone
Coelovirins E
Dactylorhin E
Dactylorhin B
Militarine
Gastrodin
1.00min, P < 0.01; and 2.56 ± 0.49min, P < 0.05), and it
prolonged their sleeping times (28.22 ± 10.50 min, P < 0.01;
and 20.81 ± 9.22 min, P < 0.05) relative to that of the control
group (7, 0.92 ± 1.58 and 8.56 ± 15.53 min), which was
induced by pentobarbital sodium at less than the threshold dose
(45mg/kg), and the diazepam group (20, 6.35 ± 0.82 and 38.22
± 3.84; P < 0.01). These results indicated that the tuber of
G. conopsea has marked sedative and hypnotic dose-dependent
effects, and its mechanism of action requires further research
(Table 4).
Preventing and Treating Gastric Ulcers
With normal saline as the control, the inhibitory effect of
the tubers on gastric ulcers was induced by hydrochloride-
ethanol solution (7.5ml/kg for 3 days, i.g.). The macroscopic
and pathological results showed that at doses of 2 and 1 g/kg,
the treatment could relieve the pathology index of gastric ulcers
induced by hydrochloride-ethanol solution and decrease the
gastric ulcer index (0.05 ± 0.13 cm and 0.22 ± 0.38 cm) at
inhibitions of 88.86% (P < 0.01) and 48.88%, respectively. The
biochemical test showed that after treatment with Gymnadeniae
tubers, the serum (9.30 ± 4.18 nmol/ml, P < 0.01; and 13.71 ±
3.89 nmol/ml) and gastric (1.10 ± 1.19 nmol/ml, P < 0.05; and
0.96 ± 0.69 nmol/ml) MDA contents could be decreased in rats.
The gastric ulcer index, MDA content in the serum and gastric
ulcer index of the model group were 0.44 ± 0.18 cm, 14.17 ±
4.88 and 3.81 ± 5.35 nmol/ml, respectively. The above results
suggest that the tubers exert a degree of inhibition on gastric
ulcers that were induced by the hydrochloride-ethanol mixture
(Lin, 2009). Jiang et al. (2009) also studied the beneficial effect
of the tuber of G. conopsea on acute gastric ulcers in rats that
were induced by hydrochloride-ethanol solution (7.5 ml/kg for 3
days). After drug administration orally (2 and 1 g/kg) for 30min,
the gastric ulcer areas were decreased with inhibitions of 88.86
(P < 0.01) and 48.88 (P < 0.01); the inhibition by a commonly
prescribed drug (ranitidine, 1.95 g/kg) was 91.12 (P < 0.01). The
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TABLE 4 | The biological activities of Gymnadenia conopsea (L.) R. Br.
Pharmacological activities Plant
parts
Processing method/extract Test
system
Animal or test organism Positive drug References
Tonifying activity Tuber Powder, no extract In vivo Mice induced by
hydrocortisone (25mg/kg,
i.g.)
– Lin, 2009
Anti-fatigue activity Tuber Aqueous extract In vivo Mice Radix ginseng,
20 g/kg
Zhao and Liu, 2011
Tuber Goat and cow milk decoction In vivo Mice – Jin and Wang, 2009
Anti-oxidant activity Tuber Methanol, aqueous and
acetone-eluted fraction
In vitro Radical scavenging assay – Morikawa et al., 2006b
Tuber Aqueous, acidic aqueous, 60%
ethanol t, 95% ethanol,
n-butanol, and n-butanol
extracts
In vitro Radical scavenging assay – Li et al., 2010
Anti-viral activity Tuber Aqueous extract In vitro The patient’s serum with
hepatitis B
– Lu et al., 2002
Sedative and hypnotic activities Tuber Powder, no extract In vivo Mice Diazepam Lin, 2009
Preventing and treating gastric
ulcers
Tuber Powder, no extract In vivo Mice induced by a
hydrochloride-ethanol
solution
– Lin, 2009
Tuber Powder, no extract In vivo Mice induced by a
hydrochloride-ethanol
solution
– Jiang et al., 2009
Immunoregulatory Activity Tuber The polysaccharide In vivo Mice – Shang et al., 2014
Anti-aging activity Tuber Shouzhangshen-37 pill (the
tuber of G. conopsea is the
primary component of this pill)
In vivo Mice induced by injecting
D-galactose
Vitamin E Si and Liu, 2013
Anti-hyperlipidemia activity Tuber Ethanol extracts In vivo Hyperlipidemia rats Lovastatin Zhang et al., 2013
Antianaphylaxis activity Tuber Methanolic extract In vivo Mice – Matsuda et al., 2004
Anti-silicosis activity Tuber 60% ethanol extract In vivo Rat lung interstitial fibrosis – Wang et al., 2007, 2008
Tuber Ethanol extract In vivo Rat lung interstitial fibrosis – Zeng et al., 2007
Tuber Ethanol extract In vivo Rat lung interstitial fibrosis – Chen, 2008
pathology of the gastric ulcers was markedly improved by these
drugs (Table 4).
Immunoregulatory Activity
As a traditional folk medicine, the tuber of G. conopsea has been
widely indicated to have good tonifying and immunoregulatory
activities (Chinese Materia Editorial Committee, State Chinese
Medicine Administration Bureau, 2002; Li et al., 2006). In
2014, Shang et al. (2014) first evaluated the immunoregulatory
functions of the polysaccharide of the tuber of G. conopsea in
mice. After administering orally the polysaccharide (100, 50, and
10 µg/g) and distilled water for 28 days, the serum lysozyme
content (104.8 ± 7.8, 102.5 ± 2.8, and 100.1 ± 7.3, all P < 0.01),
thymus index (0.42 ± 0.03, P < 0.01; 0.35 ± 0.01, P < 0.01; and
0.25± 0.02) and spleen index (0.92± 0.07, P< 0.01; 0.85± 0.04,
P < 0.01; and 0.79± 0.10, P < 0.05) were significantly improved
relative to that of the control group (86.7 ± 2.8 mg/L, 0.22 ±
0.02, and 0.72 ± 0.05 mg/g). In the delayed type hypersensitivity
(DTH) test, the drugs could promote the genesis of DTH and
induce ear swelling, especially for the high dose group (30.0± 0.4
mg, P < 0.01) compared with the control group (15.6± 0.5 mg).
The polysaccharides could significantly improve the phagocytic
function of mouse macrophages, and the phagocytosis rates were
69.6 ± 1.3 (P < 0.01), 58.6 ± 0.5 (P < 0.05) and 49.2 ± 1.0
(P < 0.05) compared with that of the control group at 40.8 ±
0.7. These results suggest that the polysaccharide has a marked
immunoregulatory function (Table 4).
Anti-Aging Activity
In 2013, Si and Liu (2013) studied the anti-aging effects and
mechanisms of the Shouzhangshen-37 pill on subacute aging
in mice (the tuber of G. conopsea is the primary component
of this pill). The subacute aging model mice were induced by
injecting D-galactose (120mg/kg) once per day for 7 weeks.
High (2.4 g/kg), middle (1.2 g/kg), and low (0.6 g/kg) doses of
Shouzhangshen-37 pills and a common drug (VE, 38.9mg/kg)
were also administered i.g. for 7 weeks. After the treatment, the
anti-aging effects and mechanisms were evaluated by observing
learning and memory ability with step-through tests, the indexes
of the brain, thymus, and spleen were calculated by measuring
the SOD, CAT, and MDA contents of brain tissues and observing
the pathomorphism changes in mouse cerebral tissue by HE
coloration. The results showed that compared with the model
group, the drugs could enhance the memory ability and decrease
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the number of mistakes within 300 s (1.54 ± 0.53, P < 0.05;
1.26± 0.42, P < 0.01; and 1.71± 0.82, P < 0.05) compared with
that of the model group (2.11± 0.81) and VE group (1.26± 0.42,
P < 0.01). In addition, the brain tissue index (12.97± 1.89mg/g,
P < 0.05; 13.39 ± 1.39mg/g, P < 0.01; and 13.05 ± 2.35mg/g, P
< 0.05), spleen (4.53 ± 0.66 mg/g, P < 0.05; 4.76 ± 0.82mg/g,
P < 0.01; and 4.58 ± 0.65mg/g, P < 0.05), and thymus (1.11 ±
0.12mg/g, P < 0.05; 1.21± 0.20 mg/g, P < 0.01; and 1.14± 0.25
mg/g, P < 0.05;) were improved compared with the model group
(10.43 ± 1.66, 3.63 ± 0.55, and 0.91 ± 0.18mg/g). The results
of the biochemical test showed that the SOD activity (170.8 ±
20.3U/mg, P < 0.05; 180.6 ± 14.7U/mg, P < 0.01; and 177.3 ±
20.1U/mg, P < 0.05) and CAT activity (6.51± 0.22, 7.14± 0.72,
and 6.32 ± 0.23U/mg, all P < 0.05) were increased and MDA
content (3.21 ± 0.98 nmol/mg, P < 0.05; 3.17 ± 0.73 nmol/mg,
P < 0.01; and 3.36 ± 0.81 nmol/mg, P < 0.05) was decreased
compared with that of the model group (156.9 ± 14.5, 5.24 ±
0.51U/mg, and 4.31 ± 0.47 nmol/mg). These results suggest that
the Shouzhangshen-37 pill has an anti-aging effect in subacute
agingmice. Themechanismmay enhance the antioxidant activity
in brain tissue, decrease the MDA content in brain tissue, protect
the brain nerve cells, and improve memory ability in mice
(Table 4).
Anti-Hyperlipidemia Activity
In 2013, Zhang et al. (2013) studied the effects of the tuber of G.
conopsea ethanol extracts on the blood lipids and liver function of
experimental hyperlipidemia rats. The results showed that after
treating the hyperlipidemia model rats that had been induced by
high-fat diets with ethanol extracts (at 5, 2.5, and 1.25 g/kg, i.g.),
the TC and LDL-C serum contents of the model rats were not
improved; however, the TG and HDL-C contents were decreased
at 1.35, 0.89, 0.97 mmol/L (P < 0.01), and 0.49 (P < 0.05),
0.53 and 0.49mmol/L (P < 0.05) compared with the model
group (2.43 and 0.64mmol/L), and the commonly prescribed
drug lovastatin also showed markedly decreased TG and HDL-
C content (P < 0.01). In addition, the ALT and AST activities
in the serum were also inhibited at10.71, 10.82, 8.21U/L (P <
0.05), 6.97 (P < 0.01), 13.60 (P < 0.05), and 18.02 U/L compared
with that of the model group, and the commonly prescribed drug
results were 8.53 (P < 0.05) and 10.38 (P < 0.01). These results
suggest that the tuber could reduce blood lipids and protect the
liver function in experimental hyperlipidemia rats (Table 4).
Antianaphylaxis Activity
In 2004, Matsuda et al. (2004) studied the effects of
the methanolic extract of the G. conopsea tuber. The
results showed an anti-allergic effect on passive cutaneous
anaphylaxis reactions in the ears of mice. The inhibitory
effects of the principal constituents on β-hexosaminidase
release, which acts as a marker of degranulation in
RBL-2H3 cells, were examined, and five phenanthrenes
(gymconopin B, 4-methoxy-9,10-dihydrophenanthrene-2,7-
diol, 1-(4-hydroxybenzyl)-4-methoxyphenanthrene-2,7-diol,
1-(4-hydroxybenzyl)-4-methoxy-9,10-dihydrophenanthrene-
2,7-diol, blestriarene A) and six dihydrostilbenes (gymconopin
D, batatasin III, 3′-O-methylbatatasin III, 3,3′-dihydroxy-2-
(4-hydroxybenzyl)-5-methoxybibenzyl, 3′,5-dihydroxy-2-(4-
hydroxybenzyl)-3-methoxybibenzyl, and 3,3′-dihydroxy-2,6-
bis(4-hydroxybenzyl)-5-methoxybibenzyl) were found to inhibit
antigen-induced degranulation by 65.5–99.4% at 100 µM in
RBL-2H3 cells (Table 4).
Anti-Silicosis Activity
Silicosis is an important occupational disease caused by the
inhalation of silica dust, and it is characterized by lung interstitial
fibrosis. In 2007 and 2008, Wang et al. (2007, 2008) studied
the effects of silica exposure on collagen synthesis in rat lungs
and mechanisms of anti-oxidative stress by using a 60% ethanol
extract of the tuber of G. conopsea. Silicotic animal models
were established by surgically directing the tracheal instillation
of silica into rat lungs. After administering the ethanol extract
orally (8 g/kg, per day), the rats were sacrificed and the samples
were collected to assay the relative index at 7, 14, 21, 28, and
60 days. The results showed that the extract could reduce the
lung/body weight ratio of rats (8.6, 6.99, P < 0.01; 7.25, P <
0.05; 7.97, P < 0.05; and 9.75mg/g, P < 0.05) relative to the
model group (11.04, 9.28, 9.11, 11.98, and 13.91mg/g), and the
extract could also improve pathological changes in the lung.
This treatment could also ameliorate silica-induced pulmonary
fibrosis by decreasing the type I and type III collagen-positive
area percentage in the lungs of rats exposed to silica at different
time points. These studies also indicated that the ethanol extract
could decrease the MDA content (4.78, P < 0.01; 5.39, P < 0.05;
5.48, P < 0.05; 5.29, P < 0.05; and 4.35mmol/L) and increase
the SOD (302.67, 243.95, P < 0.01; 293.38, P < 0.05; 277.74, P
< 0.05; and 243.36KU/L) and GPx (2199.58, 2359.34, P < 0.01;
2538.66, P < 0.01; 2422.41, P < 0.05; and 2298.04U/L) activities
relative to that of the model group (6.43, 6.88, 6.98, 6.12, and
5.82mmol/L, 314.84, 183.62, 219.41, 218.44, and 226.50KU/L,
and 2489.50, 1015.34, 1227.83, 1814.90, and 1867.38U/L). In
2007, Zeng et al. (2007) found that the ethanol extract could
reduce the TNF-α integral optical density (86.86, 105.1, 122.09,
108, and 94.88, all P < 0.01) of rat lungs compared with that
of the model group (116.98, 140.1, 220.19, 140.9, and 110.9)
at 7, 14, 21, 28, and 60 days, respectively. Before and after
treating with a 60% ethanol extract, Chen (2008) studied the
differential gene expression profiles of rat lung tissue in the
early stage exposure to silica. After treating with the extract
(8 g/kg, per day, i.g.), there were 308 and 231 up-regulated
and down-regulated genes among a total of 539 available genes
compared with that of the model group. Up-regulated pathways
might be associated with cell adhesion molecules, notch signaling
pathways, and leukocyte transendothelial migration and cell
communication. Down-regulated pathways might be related
to genes in the linkage of complementary and coagulation
cascades, hematopoietic cell lineages, urea cycle and Alzheimer’s
disease. The chip results were verified by using real-time PCR
for SOD and HMOX genes with the same trends. Thus, the
investigators indicated that the alcohol extract may inhibit
silicosis progress during early exposure periods and attenuate
airs acculitis and fibrosis of the lung. The results also showed
that the ethanol extract (8 g/kg, per day, i.g.) has the reverse
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effect on silicosis, and this process involved the cathepsin D
precursor SEC14-like protein 3 and peroxiredoxin-1 (Chen,
2009; Table 4).
Other Activities
In 2008, Zi (2008) studied the anti-cancer activity of certain
compounds from the tuber of G. conopsea. The results showed
that the IC50-value of (−)-4-[β-D-glucopyranosyl-(1→4)-β-D-
glucopyranosyloxy] benzyl alcohol against human hepatoma
cancer cells (Bel7402) was 3.818 µM compared with the
commonly prescribed drug camptothecine at 12.5 µM. At a
concentration of 10−6 mol/L, gastrodin was active against serum
deprivation-induced SH-SY5Y apoptosis.
At a dose of 5 mg/kg (i.p.), dactylorhin B, coelovirin E and
(2R,3S)-1-(4-hydroxybenzyl)-2-hydroxy-4-(4-hydroxybenzyl)-
2-isobutyltartrate could improvemouse memory deficits induced
by scopolamine with a neuroprotective effect. Coelovirin E and
(2R,3S)-1-(4-hydroxybenzyl)-2-hydroxy-4-(4-hydroxybenzyl)-
2-isobutyltartrate could extend the latent time for the step-down
test in mice with improvements of 65 and 106%, respectively (Zi,
2008; Table 4).
PREPARATIONS AND QUALITATIVE AND
QUANTITATIVE ANALYSIS
G. conopsea has been widely used as a folk medicine in the
treatment or prevention of diseases for thousands of years in
China, but it has not been listed in the Chinese pharmacopeia
because there is a lack of scientific quality standards to
control the quality of the tuber since 1977 (Committee for
the Pharmacopoeia of P.R. China, 1977, 2000; Chinese Materia
Editorial Committee, State Chinese Medicine Administration
Bureau, 2002). Recently, experts have attempted to formulate the
proper quality standard by analyzing the active compounds and
determining the contents of plants from different habitats with
different chromatographic equipment.
Now, as a strategy to control the quality of folk medicines,
chemical fingerprint analyses have been accepted by the
WHO (1991), State Food and Drug Administration of China
(2000), and other authorities, which has been recognized as
a rapid and reliable method of identifying and qualifying
herbal medicines. Cai et al. (2006) first developed a high-
performance liquid chromatography-diode array detection-
tandem mass spectrometry (HPLC-DAD-MSn) method for the
chemical fingerprint analysis and rapid identification of major
compounds in G. conopsea tubers. An HPLC separation was
performed by using a linear gradient at room temperature
(20◦C) and a flow rate of 0.7ml/min with an Inertsil C18 ODS-
3 column. The gradient elution started with a methanol: water
mixture (20:80, v/v), and the methanol content was increased to
100% within 60 min; the detection wavelength for fingerprint
analysis was 270 nm. Adenosine, 4-hydroxybenzyl alcohol, 4-
hydroxybenzyl aldehyde, dactylorhin B, loroglossin, dactylorhin
A, and militarine were well-separated and identified from the
tuber of 10 samples, which were collected from Sichuan, Qinghai,
and Hebei Provinces and Tibet Autonomous Region of China
and Nepal. Xue et al. (2013) also studied the fingerprint of G.
conopsea by using HPLC. Their samples were separated on a
Kromasil C18 (4.6 × 250mm, 5 µm) column and gradient-
eluted with a mixture of methanol and water (0.04% phosphoric
acid) at a flow rate 0.7ml/min; the detection wavelength was set
at 222 nm, and the column temperature was 30◦C. The results
showed that 13 common peaks were selected, and the method
validation met the technical requirements of a fingerprint.
The similarity of 12 samples from the different regions of
the Xizang Autonomous Region and Qinghai Province was
0.904–0.989. The above two methods are simple, practical and
reliable. The combined use of the two fingerprints confirmed
the identification and quality assessment of G. conopsea. In
2009, after investigating the optimal extraction method, Li et al.
(2009) firstly developed a HPLC method for the simultaneous
quantification of five glucosyloxybenzyl 2-isobutylmalates in the
tubers of G. conopsea, which was collected at five regions in
China. The optimal extraction conditions was the direct reflux
with 70% ethanol for 1 h, and the compounds are separated
on an Agilent Hydrosphere C18 (150 × 4.6 mm i.d., 5 µm)
column using a mobile phase of acetonitrile-water including
0.3% acetic acid (adjusted with 36% acetic acid) with gradient
elution at a flow rate of 1.0 mL/min. Detection is set at a
UV wavelength of 221.5 nm. The recovery of the method is
97.7–101.0%, and linearity (r > 0.9998) is obtained for all the
analytes. The results showed that the contents of dactylorhin B,
dactylorhin E, loroglossin, dactylorhin A, and militarine were
1638.28, 100.19, 279.91, 717.22, and 101.78mg/g (Lijiang City,
Yunan Province), 665.82, 92.12, 248.15, 507.65, and 138.57mg/g
(Weixian City, Hebei Province), 707.84, 85.64, 322.63, 705.70,
and 137.30mg/g (Kangding City, Sichuan Province), 2207.30,
204.46, 604.81, 2213.39, and 228.04 mg/g (Xizang Autonomous
Region), and 4073.89, 156.81, 3060.63, 2230.67, and 563.56mg/g
(Xining City, Qinghai Province). Yang et al. (2009) and Yang
(2010) determined the contents of four marker compounds
from the tubers of Gymnadenia conopsea (L.) R. Br. by HPLC,
and the tubers were collected from 24 regions, including the
Sichuan Province, Xizang Autonomous Region, Jilin Province,
Heilongjiang Province, Qinhai Province, and other regions
in China. At a detection wavelength of 222 nm, the mobile
phases of methanol (A) and water (B) were used in a gradient
elution at 0.7ml/min. The initial condition was 15–20% A
in 0–10min, which increased to 45% A in 20min and 70%
A in 35min. The results showed that the highest contents
of dactylorhin A, dactylorhin B, loroglossin, and militarine
from the rhizomes of24 different regions were 1.428 and
1.638mg/g from Lulang County in the Xizang region and 1.148
and 0.521 mg/g from Jilin Province. In 2011, the gastrodin
contents were assayed by HPLC, and the results showed that the
highest content was 9.113 mg/g in Tongde County of Qinghai
Province, China, followed by 7.785mg/g (Beinagou region,
Qinghai Province), 4.881mg/g (Huangnan Zeku region, Qinghai
Province), 4.309mg/g (Guoluo region, Qinghai Province),
4.285mg/g (Batang Grassland, Qinghai Province), 3.895mg/g
(Nangqian County, Qinghai Province), 3.719mg/g (Maixiu
Forest Farm, Qinghai Province), 3.242mg/g (Jinyingtan, Qinghai
Province), 3.024mg/g (Linzhi County, Xizang Autonomous
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Region), 3.103mg/g (Chengduo, Qinghai Province), 2.734mg/g
(Bomi County, Xizang Autonomous Region), and 2.268mg/g
(Beishan Forest Farm, Huzhu County, Qinghai Province; Xue
et al., 2011).
Meanwhile, the content of four marker constituents of the
tubers with the climatic factors were determined and analyzed
by HPLC in 2014. The results showed that the samples collected
from Milin County in the Xizang Autonomous Region had the
highest gastrodin content at 2.725mg/g, and the Shennongjia
region of Hubei Province had lowest content at 0.374 mg/g. The
samples collected from Kangding County of Sichuan Province,
Aba region of Sichuan Province and Naqu County of the Xizang
Autonomous Region had the highest contents of adenosine,
4-hydroxybenzyl alcohol and 4-hydroxybenzaldehyde at 1.485,
1.505, and 1.048mg/g, respectively. These findings suggest
that the average temperature and annual average variations in
monthly temperature change along with seasonal variations, and
the highest temperature, variations in the scope of the annual
temperature, average temperature of the most humid season,
average temperature of the hottest season, annual rainfall, rainfall
during the driest season, rainfall during the coldest season, and
latitude and altitude of the habitat can have an effect on the active
ingredient content and quality of the tuber ofG. conopsea (Zhang
et al., 2014).
The study results also indicated that the samples
collected from Huzhu County of Qinghai Province had the
highest contents of gastrodin (4.9242mg/g), dactylorhin A
(8.2274mg/g), and militarine (7.4645mg/g; Yao and Lin, 2014).
TOXICITY
In 2007, Bai and Zheng (2007) evaluated the toxicity of the tuber
of G. conopsea. In acute toxicity test, after administering the
tuber (1.00, 2.15, 4.64, and 10 g/kg, i.g.) to mice and rats, the
behavior, and growth of the animals did not change after 2 weeks
compared to the control group (P > 0.05), and the LD50 was
more than 10 g/kg. The genotoxicity of the medicine was then
studied, and the results showed that the rates of bonemarrow and
sperm abnormalities were not changed compared with that of
the control group, but the sperm abnormality rates of the group
administered a common drug (cyclophosphamide, 30 mg/kg)
changed markedly (P < 0.01). And after administering the tuber
(1.67, 3.33, and 6.67 g/kg, i.g) to rats for 30 days, the parameters of
blood routine, biochemical indexes, organ coefficient, and organ
pathology of rats haven’t marked changed compared the control
group (P > 0.05). So they thought that the tuber didn’t present
the apparent toxicity.
CONCLUSIONS AND FUTURE
PERSPECTIVES
As an important traditional medicine in China, the tuber of
G. conopsea has been historically used in a number of clinical
applications. However, lack of scientific quality standard to
control the quality of the tuber has been hampered to the
development of this plant. Up to now although investigators
have begun studying and developing the quality of the tuber
and its preparations by analyzing the marker compounds and
determining the contents of plants from different habitats, a
scientific method to control the quality of these products has
not yet been developed and approved by government. Thus, a
characteristic chemical and biological index should be established
to monitor and evaluate quality of samples and maintain
their clinical and pharmaceutical stability, and the method of
accurately controlling the quality of the tuber in traditional
medicine and preparations should be studied further.
With the excavation and abundant use of G. conopsea, as well
as the over-grazing and disorder tourism resulted in the habitat
destruction, the resources of this plant were rapid decreased. At
the same time, because of the low reproductive capacity of this
plant, once the resources and habitat have been destroyed, the
species does not recover easily. In 2000, G. conopsea has been
listed in the grade 5 section of endangered species (Gesang
and Gesang, 2010). Recently, investigators have begun studying
and developing methods of cultivating this plant, such as tissue
culture and artificial breeding, but this technology is still not
applied in industry (Bao et al., 2008). Therefore, the sustainable
use of G. conopsea is necessary to investigate. Of course, along
with the decrease of resources, the studies on the aerial part
should be paid more attention, especially for finding new active
compounds and bioactivities.
In a word, phytochemical and pharmacological studies of
G. conopsea have received great interest, and an increasing
number of extracts and active compounds have been isolated
that have demonstrated tonifying activity, anti-viral activity
and immunoregulatory activity, among others. However,
validating the correlations of the ethnomedicinal uses and
pharmacological effects should be carried out further, and the
toxicity of this plant also should be studied systematically.
Meanwhile, the poor quality control, decreased resources, the
increasing gap between more experience-based traditional
uses and less evidence-based clinical trials for the tuber of G.
conopsea has created challenges. Therefore, this plant should
be studied and developed further, especially in the resource
conservation.
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